Ticagrelor and platelet reactivity in acute coronary syndromes
Acute Coronary Syndrome patients and the effects of ticagrelor loading dose on level of platelet inhibition
Peter Larsen
50 participants
Dec 9, 2013
Interventional
Conditions
Summary
Following a heart attack we give all patients drugs that act on platelets that circulate in the blood. These drugs, aspirin and ticagrelor, act on the platelets to limit the amount of blood clotting that occurs following the heart attack. The standard amount of ticagrelor we give people initially is 180mg. A study has shown that with this amount of the drug it can take 8 to 12 hours until the full effect of the drug is observed. We want to know if by doubling the initial dose to 360mg we can reduce the time it takes to see the full effects.
Eligibility
Inclusion Criteria1
- Acute coronary syndrome
Exclusion Criteria3
- Known platelet function disorder
- Platelet count less than 100
- Prior administration of a P2Y12 receptor antagonist within 2 weeks
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Randomised, double-blind clinical trial comparing the effects of a single 180mg Ticagrelor loading dose given orally (control) with a single 360mg Ticagrelor loading dose given orally (intervention) on platelet inhibition in patients with acute coronary syndromes. This is the initial treatment, following which patients will undergo angiography. Depending on the findings at angiography patients may be prescribed dual anti platelet therapy (ticagrelor and aspirin) daily for up to 1 year, but this is beyond the scope of this study, which is only investigating the effects of the initial loading dose.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001208796